Home/Pipeline/MIP Test for MS Monitoring

MIP Test for MS Monitoring

Multiple Sclerosis

NAActive

Key Facts

Indication

Multiple Sclerosis

Phase

Status

Active

Company

DxTerity

About DxTerity

DxTerity is a private, commercial-stage diagnostics company leveraging RNA expression profiling to advance precision medicine in autoimmune diseases. Its core technology, the Modular Immune Profile (MIP), analyzes immune-related gene expression from a simple at-home blood sample to monitor disease activity and treatment response. The company has validated its platform through multiple clinical studies (LIFT, EMPOWER, ELEVATE) and collaborates with research institutions and pharma partners. DxTerity operates on a diagnostics business model, generating early revenue from test kits and research services while aiming to secure broader insurance reimbursement.

View full company profile

Therapeutic Areas

Autoimmune Diseases Lupus Erythematosus, Systemic Multiple Sclerosis

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active